Novartis Records $1.9 Billion Charge After Trial Failure
The clinical setback for del-desiran forces the firm to re-evaluate its development costs while maintaining its M&A strategy.
Updated on Oct. 27, 2026 in Healthcare
Live Poll
Should large pharmaceutical companies focus on smaller acquisitions to mitigate risks after clinical trial failures?
Novartis recorded a $1.9 billion impairment charge in Q3 2026 after its del-desiran candidate failed to meet primary endpoints in a phase 3 myotonic dystrophy trial. This clinical setback occurs alongside a clinical hold on its rapcabtagene autoleucel program following three patient deaths.
Why it matters
The charges and trial holds underscore the significant financial risks inherent in pharmaceutical R&D, where substantial capital investments can be wiped out by single clinical failures. For operators, this highlights the necessity of maintaining diversified portfolios to absorb potential multi-billion dollar losses.
Novartis recognized a $1.9 billion impairment charge in Q3 2026 following the failure of a phase 3 trial, a loss measured against the company's $12 billion 2025 investment in Avidity Biosciences. The firm also reported three patient deaths linked to its rapcabtagene autoleucel program.
The players
Novartis
A Swiss-headquartered global pharmaceutical company focused on researching and developing innovative healthcare solutions.
Vas Narasimhan
The CEO of Novartis responsible for the company's long-term growth outlook and M&A strategy.
Avidity Biosciences
A biotechnology firm specializing in oligonucleotide-based therapies acquired by Novartis for $12 billion.
The details
The $1.9 billion charge reflects the costs of re-evaluating the del-desiran program, including requirements for an additional pivotal study. Meanwhile, the rapcabtagene autoleucel program remains on clinical hold in the U.S. and Europe after patients experienced complications leading to immune effector cell-associated hemophagocytic syndrome. Despite these setbacks, the company intends to maintain its current M&A strategy.
Timeline
2025-10: Novartis completed the $12 billion acquisition of Avidity Biosciences.
Summer 2026: Novartis paused development of rapcabtagene autoleucel.
September 2026: The phase 3 clinical trial for del-desiran failed.
Q3 2026: Novartis recorded a $1.9 billion impairment charge.
Market Landscape
This impairment charge follows the firm's $12 billion 2025 acquisition of Avidity Biosciences, highlighting the high-stakes volatility inherent in major pharmaceutical R&D spending. The result marks a departure from anticipated clinical successes that typically justify such large-scale capital deployment.
Operators in high-R&D sectors should monitor how large enterprises adjust their capital allocation strategies after clinical failures. Diversification of asset classes remains the primary defense against localized losses.
The takeaway
Large-scale investments in research require rigorous contingency planning for failed clinical milestones. Operators should track the company's updates on the rapcabtagene autoleucel clinical hold to evaluate the effectiveness of their ongoing safety protocols.
What happens next
Novartis plans to provide updates on the rapcabtagene autoleucel clinical hold in the coming months.
Further reading
For broader insights on industry R&D risks, explore our latest coverage in Healthcare.
Live Poll
Should large pharmaceutical companies focus on smaller acquisitions to mitigate risks after clinical trial failures?
